Mind + Muscle

technical minds + legal muscle


dig deep

FDA Accepts the First Biosimilar Application under the BPCIA

  • 07.24.14
  • Paul A. Calvo, Ph.D.
  • Sterne, Kessler, Goldstein & Fox

Sandoz announced today that the FDA accepted its Biologics License Application (BLA) for filgrastim. This marks the first acceptance of a biosimilars application (351(k)) filed under the pathway created by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).  Although it has taken four years for the first 351(k) application to be filed, acceptance of Sandoz’s application is the first step towards approval of the first biosimilar biologic in the United States.

To read our full summary, download the attached PDF.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.